Microbix Biosystems Inc. (TSX: MBX), a biotechnology company commercializing novel technologies to enhance vaccine production yields, and other innovative biologics, announced today that the European Patent Office recently granted patent protection for the company's proprietary VIRUSMAX™ technology, which is designed to increase influenza vaccine yields and has demonstrated an average yield increase of at least two-fold over current vaccine production methods.

The newly granted European Patent No. EP 1636352 entitled "Improvement in Virus Production," covers the material, process and use of the VIRUSMAX technology that is the basis for the Microbix/Hunan Joint venture - which is underway to build Asia's largest influenza vaccine production facility and the third largest vaccine plant in the world. The first phase of the facility is expected to be fully operational in 2013.

Crucible International Biotechnologies Corp., a majority-owned subsidiary of Microbix, is facilitating the start-up and operation of this joint venture and will advance the commercialization of its VIRUSMAX™ technology in other markets, which are protected by patents that run well beyond the next decade. The new facility in China will ultimately have the capacity to produce more than 100 million doses of seasonal influenza vaccine annually, and up to 300 million doses of a pandemic influenza vaccine in the event of an outbreak to immunize against a single strain of influenza.

William J. Gastle, Microbix' Chief Executive Officer, said: "With the European patent in hand, Microbix' vaccine enhancement technology has patent protection in the world's largest markets. We can now look for further opportunities for VIRUSMAX, beyond the China market, with a dominant patent estate."

Source: MICROBIX BIOSYSTEMS INC

Microbix生物系统公司（TSX：信箱），一家生物技术公司商业化新技术，以提高疫苗生产产量，生物制品和其他创新，今天宣布，欧洲专利局最近授予专利保护，该公司专有的VIRUSMAX™技术，其目的是提高流感疫苗的产量，并显示了对疫苗的生产方法，目前的平均收益率的提高，至少有两个方面。

新授权的欧洲专利EP 1636352号题为“改善体内病毒的生产”，包括材料，工艺和技术，VIRUSMAX为Microbix /湖南省合资基础上使用 - 这是正在建设亚洲最大的流感疫苗生产设施和世界第三大疫苗厂。该设施的第一阶段预计在2013年全面投入运营。

坩埚国际生物技术公司是一家Microbix拥有多数股权的子公司，是促进这个合资企业的启动和操作，将推进其VIRUSMAX™在其他市场，这是受专利保护的技术商业化运行超出了良好下一个十年。在中国的新工厂将最终有能力生产100多万剂季节性流感疫苗每年，多达3亿剂流感大流行应变单一的流感疫苗事件一爆发针对免疫。

威廉J Gastle，Microbix公司首席执行官说：“随着欧洲专利在手，Microbix'疫苗强化技术具有专利保护的市场在世界上最大的。现在，我们可以寻找机会，为中国进一步VIRUSMAX，超出了市场专利与主导产业。“

来源：Microbix生物系统有限公司